Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
As a result, Imago will become a subsidiary of Merck.
Acquisition expands Merck’s growing hematology portfolio
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
